How much is Endeavor BioMedicines worth in 2026?

Endeavor BioMedicines has a current valuation of N/A based on their Later Stage VC (Series C) round and secondary market data.

How much funding has Endeavor BioMedicines raised?

Endeavor BioMedicines has raised N/A in total funding across 1 funding rounds.

Endeavor BioMedicines

Drug Discovery

Endeavor BioMedicines valuation and funding history | Last updated: April 24, 2024 | 1 funding rounds

Current Valuation

N/A

As of April 24, 2024

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series C)

$132.5M

Last Funding

Apr 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
April 24, 2024	Later Stage VC (Series C)	$132.5M	N/A	-

Valuation Analysis

Current Valuation Metrics

Endeavor BioMedicines is currently valued at N/A as of April 24, 2024.

Track Endeavor BioMedicines Valuation Updates

Get notified when Endeavor BioMedicines raises new funding or valuation changes

Explore More Data

Detailed analysis for Endeavor BioMedicines

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Endeavor BioMedicines's valuation history, funding rounds, and growth metrics.

No credit card required

What is Endeavor BioMedicines Worth in 2026?

Endeavor BioMedicines is a leading private company in the Drug Discovery sector. Track Endeavor BioMedicines's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Endeavor BioMedicines Valuation is Determined

Private company valuations like Endeavor BioMedicines's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.